<DOC>
	<DOCNO>NCT02581202</DOCNO>
	<brief_summary>This study seek assess virologic effectiveness dual therapy ( lopinavir/ ritonavir ( LPV/r ) + lamivudine ( 3TC ) ) treatment-experienced human immunodeficiency virus 1 ( HIV-1 ) infect participant undetectable plasma HIV-1 ( ribonucleic acid ) RNA level ( least 6 month ) 48 week time point treatment routine clinical setting Russian Federation .</brief_summary>
	<brief_title>The Effectiveness Dual Therapy ( Lopinavir/Ritonavir + LamivudinE ) Treatment-Experienced HIV Infected Patients Russian Federation</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . Age 18 year old ( male female ) . 2 . HIV1 infect patient triple HAART plasma HIV1 RNA level &lt; 50 copies/mL least 6 month ( two consequently plasma HIV1 RNA level ) transfer medically appropriate LPV/r + 3TC decide physician routine clinical setting . OR HIV1 infect patient switch dual therapy ( LPV/r + 3TC ) 60 day ago . 3 . Cumulative HAART experience least 6 month . 4 . Authorization ( Consent ) Use/Disclosure Data sign patient . 1 . Contraindications lopinavir/ritonavir lamivudine 2 . Previous participation program</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>antiretroviral therapy</keyword>
</DOC>